FDA Greenlights New Myasthenia Gravis Drug
The FDA approved rozanolixizumab-noli (Rystiggo), a neonatal Fc receptor blocker, to treat adults with generalized myasthenia gravis (gMG), UCB announced Tuesday. The drug is the first approved to treat both of the two most common subtypes of gMG patients — those who are anti-acetylcholine receptor (AChR)-positive and those who are anti-muscle-specific tyrosine kinase (MuSK) antibody-positive. […]